Aziyo Biologics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.1001
- Today's High:
- $1.3
- Open Price:
- $1.17
- 52W Low:
- $1.1
- 52W High:
- $9.01
- Prev. Close:
- $1.32
- Volume:
- 150877
Company Statistics
- Market Cap.:
- $40.43 million
- Book Value:
- -0.752
- Revenue TTM:
- $50.74 million
- Operating Margin TTM:
- -47.72%
- Gross Profit TTM:
- $19.22 million
- Profit Margin:
- -64.49%
- Return on Assets TTM:
- -25.11%
- Return on Equity TTM:
- -775.14%
Company Profile
Aziyo Biologics Inc had its IPO on 2020-10-08 under the ticker symbol AZYO.
The company operates in the Healthcare sector and Medical Devices industry. Aziyo Biologics Inc has a staff strength of 164 employees.
Stock update
Shares of Aziyo Biologics Inc opened at $1.17 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.1 - $1.3, and closed at $1.26.
This is a -4.55% slip from the previous day's closing price.
A total volume of 150,877 shares were traded at the close of the day’s session.
In the last one week, shares of Aziyo Biologics Inc have slipped by -16%.
Aziyo Biologics Inc's Key Ratios
Aziyo Biologics Inc has a market cap of $40.43 million, indicating a price to book ratio of 13.3419 and a price to sales ratio of 1.2859.
In the last 12-months Aziyo Biologics Inc’s revenue was $50.74 million with a gross profit of $19.22 million and an EBITDA of $-20462000. The EBITDA ratio measures Aziyo Biologics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aziyo Biologics Inc’s operating margin was -47.72% while its return on assets stood at -25.11% with a return of equity of -775.14%.
In Q1, Aziyo Biologics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 13.5%.
Aziyo Biologics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.5 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aziyo Biologics Inc’s profitability.
Aziyo Biologics Inc stock is trading at a EV to sales ratio of 1.6534 and a EV to EBITDA ratio of -2.8249. Its price to sales ratio in the trailing 12-months stood at 1.2859.
Aziyo Biologics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $60.63 million
- Total Liabilities
- $41.42 million
- Operating Cash Flow
- $-182000.00
- Capital Expenditure
- $182000
- Dividend Payout Ratio
- 0%
Aziyo Biologics Inc ended 2024 with $60.63 million in total assets and $0 in total liabilities. Its intangible assets were valued at $60.63 million while shareholder equity stood at $-12175000.00.
Aziyo Biologics Inc ended 2024 with $0 in deferred long-term liabilities, $41.42 million in other current liabilities, 16000.00 in common stock, $-145962000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $11.79 million and cash and short-term investments were $11.79 million. The company’s total short-term debt was $10,266,000 while long-term debt stood at $24.59 million.
Aziyo Biologics Inc’s total current assets stands at $43.47 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $18.26 million compared to accounts payable of $3.50 million and inventory worth $11.06 million.
In 2024, Aziyo Biologics Inc's operating cash flow was $-182000.00 while its capital expenditure stood at $182000.
Comparatively, Aziyo Biologics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.26
- 52-Week High
- $9.01
- 52-Week Low
- $1.1
- Analyst Target Price
- $12
Aziyo Biologics Inc stock is currently trading at $1.26 per share. It touched a 52-week high of $9.01 and a 52-week low of $9.01. Analysts tracking the stock have a 12-month average target price of $12.
Its 50-day moving average was $1.88 and 200-day moving average was $2.91 The short ratio stood at 0.55 indicating a short percent outstanding of 0%.
Around 119.7% of the company’s stock are held by insiders while 7860.4% are held by institutions.
Frequently Asked Questions About Aziyo Biologics Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative products to address the device protection, women’s health, orthobiologics, cardiovascular, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.